Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Excellence Forum

Diffuse Large B-Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Aine Hurley, MD
Conference Coverage
New Third Generation CAR-T Therapy Targets LBCL With Lower Toxicity Risk: ENABLE-2
06/26/2025
Aine Hurley, MD
Aine Hurley, MD shares insights into the ENABLE-2 clinical trial determining the safety and efficacy of WZTL-002 for patients with relapsed/refractory large B-cell lymphoma.
Aine Hurley, MD shares insights into the ENABLE-2 clinical trial determining the safety and efficacy of WZTL-002 for patients with relapsed/refractory large B-cell lymphoma.
Aine Hurley, MD shares insights...
06/26/2025
Oncology
Krish Patel, MD
Conference Coverage
Dual-Target CAR T-Cell Therapy Demonstrates Promising Response Rates for R/R LBCL
06/23/2025
Krish Patel, MD
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish...
06/23/2025
Oncology
Tae Min Kim, MD
Conference Coverage
AZD0486 Demonstrates Early Efficacy for R/R DLBCL With Manageable Safety Profile
06/16/2025
Tae Min Kim
At the 2025 ASCO Annual Meeting, Tae Min Kim, MD shares results from a phase 1 clinical trial assessing the safety and efficacy of AZD0486 for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
At the 2025 ASCO Annual Meeting, Tae Min Kim, MD shares results from a phase 1 clinical trial assessing the safety and efficacy of AZD0486 for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
At the 2025 ASCO Annual Meeting,...
06/16/2025
Oncology
Russell Gollard, MD
Conference Coverage
Evaluating Zilovertamab Vedotin Plus R-CHOP as Frontline Therapy for Patients With DLBCL: waveLINE-010
06/13/2025
Russell Gollard, MD
Russell Gollard, MD discusses the waveLINE-010 study assessing the efficacy and safety of zilovertamab vedotin plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of diffuse large B-cell lymphoma.
Russell Gollard, MD discusses the waveLINE-010 study assessing the efficacy and safety of zilovertamab vedotin plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of diffuse large B-cell lymphoma.
Russell Gollard, MD discusses...
06/13/2025
Oncology
Nilanjan Ghosh, MD, PhD
Videos
Advancements in Treatment Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
04/09/2025
Nilanjan Ghosh, MD, PhD
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP...
04/09/2025
Oncology
Michael Green, PhD
Conference Coverage
Potential Impact of Classification of R/R Diffuse Large B-Cell Lymphoma Microenvironment Archetypes on Patient Treatment and Outcomes
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
Matthew Matasar, MD, MS
Videos
Odronextamab Monotherapy Shows Encouraging Efficacy, Manageable Safety for DLBCL Progressing After CAR-T Therapy
12/10/2024
Matthew Matasar, MD
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses...
12/10/2024
Oncology
Nirav Shah, MD
Videos
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
12/08/2024
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses...
12/08/2024
Oncology
Alaa Ali, MD, Lombardi Comprehensive Cancer Center
Videos
Fludarabine- vs Bendamustine-Based Lymphodepletion Prior to CAR-T Therapy for Relapsed/Refractory DLBCL
12/08/2024
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting,...
12/08/2024
Oncology
Jean-Nicolas Champagne, MD, BC Cancer Vancouver
Videos
Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
12/08/2024
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD,...
12/08/2024
Oncology

Recent Stories

Aine Hurley, MD
Conference Coverage
New Third Generation CAR-T Therapy Targets LBCL With Lower Toxicity Risk: ENABLE-2
06/26/2025
Aine Hurley, MD
Aine Hurley, MD shares insights into the ENABLE-2 clinical trial determining the safety and efficacy of WZTL-002 for patients with relapsed/refractory large B-cell lymphoma.
Aine Hurley, MD shares insights into the ENABLE-2 clinical trial determining the safety and efficacy of WZTL-002 for patients with relapsed/refractory large B-cell lymphoma.
Aine Hurley, MD shares insights...
06/26/2025
Oncology
Krish Patel, MD
Conference Coverage
Dual-Target CAR T-Cell Therapy Demonstrates Promising Response Rates for R/R LBCL
06/23/2025
Krish Patel, MD
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish...
06/23/2025
Oncology
Tae Min Kim, MD
Conference Coverage
AZD0486 Demonstrates Early Efficacy for R/R DLBCL With Manageable Safety Profile
06/16/2025
Tae Min Kim
At the 2025 ASCO Annual Meeting, Tae Min Kim, MD shares results from a phase 1 clinical trial assessing the safety and efficacy of AZD0486 for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
At the 2025 ASCO Annual Meeting, Tae Min Kim, MD shares results from a phase 1 clinical trial assessing the safety and efficacy of AZD0486 for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
At the 2025 ASCO Annual Meeting,...
06/16/2025
Oncology
Russell Gollard, MD
Conference Coverage
Evaluating Zilovertamab Vedotin Plus R-CHOP as Frontline Therapy for Patients With DLBCL: waveLINE-010
06/13/2025
Russell Gollard, MD
Russell Gollard, MD discusses the waveLINE-010 study assessing the efficacy and safety of zilovertamab vedotin plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of diffuse large B-cell lymphoma.
Russell Gollard, MD discusses the waveLINE-010 study assessing the efficacy and safety of zilovertamab vedotin plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of diffuse large B-cell lymphoma.
Russell Gollard, MD discusses...
06/13/2025
Oncology
Nilanjan Ghosh, MD, PhD
Videos
Advancements in Treatment Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
04/09/2025
Nilanjan Ghosh, MD, PhD
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP...
04/09/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use